




JOHNS HOPKINS
BLOOMBERG SCHOOL
of PUBLIC HEALTH

New Jersey Drug Treatment Program Survey Results

Kathryn N. Burke, MPH
Kenneth A. Feder, PhD

Background

- ▶ **Purpose:** Understand how state-licensed substance use treatment programs are integrating medications for opioid use disorder (MOUD) into their treatment programs and what challenges are being encountered
- ▶ **Goal:** Use information gathered to develop strategies that can help support the use of MOUD in treatment
- ▶ The New Jersey Drug Treatment Program Survey was open from November 10, 2022 – January 18, 2023



 NJ Human Services

Division of Mental Health and Addiction Services (DMHAS)
Survey of Licensed Substance Use Agencies

Today's date: 1/18/2023

Name of program:

Facility or site license number:

Site address:


Methodology

- ▶ Survey was designed with input from DMHAS, MOUD Interest Group, and stakeholders from substance use agencies in New Jersey
- ▶ Survey was distributed via email to all licensed substance use agencies in New Jersey
 - ▶ Three reminder emails were sent
- ▶ 130 responses were received from 452 potential respondents (response rate of 29%)
 - ▶ **102 Non-OTPS**
 - ▶ 21 OTPs
 - ▶ 7 organizations did not serve clients with OUD



Organization type

► Which best describes your **organization type**? (n = 123)



Note: Data for organizations that treat clients with OUD is shown.



JOHNS HOPKINS


BLOOMBERG SCHOOL
of PUBLIC HEALTH

Medications provided



Client use of MOUD

- ▶ To your best guess, please select the **proportion of OUD patients at your facility that currently take MOUD.**




Provision of MOUD

► Please select the option that best describes your site's **provision of MOUD**. (n = 102)




Provision of MOUD: On-site

- ▶ Please select what **forms of MOUD** your program provides onsite. (Select all that apply) (n = 64)



Provision of MOUD: Off-site

► Please select what **forms of MOUD** your program provides off-site. (Select all that apply)
(n = 16)





JOHNS HOPKINS


BLOOMBERG SCHOOL
of PUBLIC HEALTH

Beliefs about MOUD



Beliefs about MOUD

- ▶ **To what extent do you believe the following treatments can be helpful as part of a client's treatment plan?**





JOHNS HOPKINS


BLOOMBERG SCHOOL
of PUBLIC HEALTH

Barriers to the use of MOUD




Barriers to MOUD: Program staff attitudinal barriers

- ▶ Please indicate to what extent you believe each of the following are **barriers to the use of buprenorphine**, specifically, as part of OUD clients' treatment plan.




Barriers to MOUD: Client and family attitudinal barriers

- ▶ Please indicate to what extent you believe each of the following are **barriers to the use of buprenorphine**, specifically, as part of OUD clients' treatment plan.




Barriers to MOUD: Cost and insurance barriers

- ▶ Please indicate to what extent you believe each of the following are **barriers to the use of buprenorphine**, specifically, as part of OUD clients' treatment plan.




Barriers to MOUD: Other institutional barriers

- ▶ Please indicate to what extent you believe each of the following are **barriers to the use of buprenorphine**, specifically, as part of OUD clients' treatment plan.




Barriers to MOUD: Government and regulatory barriers

- ▶ Please rate to what extent you believe the following **actions by government agencies** could increase uptake of buprenorphine as part of OUD clients' treatment plan.




Barriers to MOUD: Regulatory barriers

- ▶ Please rate to what extent you believe the following **actions by government agencies** could increase uptake of buprenorphine as part of OUD clients' treatment plan.



Barriers to MOUD: Race and ethnicity

- ▶ Do you think there are **barriers or factors related to race or ethnicity**, including language barriers, that additionally impede the ability of clients to access MOUD? (n = 120)






JOHNS HOPKINS

BLOOMBERG SCHOOL
of PUBLIC HEALTH

Measures of client progress & dismissal criteria


Measures of client progress

- ▶ Please choose whether each indicator is "Very important," "Important," "Slightly important," "Not important," or "Not applicable" for **measuring your clients' progress**.




Measures of client progress continued

- ▶ Please choose whether each indicator is "Very important," "Important," "Slightly important," "Not important," or "Not applicable" for **measuring your clients' progress**.




Measures of client progress continued

- ▶ Please choose whether each indicator is "Very important," "Important," "Slightly important," "Not important," or "Not applicable" for **measuring your clients' progress**.




Criteria for client dismissal

- ▶ Please choose whether each indicator is "Very important," "Important," "Slightly important," "Not important," or "Not applicable" for **determining whether to dismiss or transfer a client from your treatment program.**




Criteria for client dismissal continued

- ▶ Please choose whether each indicator is "Very important," "Important," "Slightly important," "Not important," or "Not applicable" for **determining whether to dismiss or transfer a client from your treatment program.**



Criteria for client dismissal continued

- ▶ Please choose whether each indicator is "Very important," "Important," "Slightly important," "Not important," or "Not applicable" for **determining whether to dismiss or transfer a client from your treatment program.**





JOHNS HOPKINS

BLOOMBERG SCHOOL
of PUBLIC HEALTH

Key findings & next steps



Key findings for discussion

- ▶ **Most organizations offer MOUD** either on- or off-site (72%)
- ▶ Most organizations estimate that **less than a quarter of clients at their facility use MOUD**
- ▶ **Client cost and insurance barriers** were predominant over attitudinal barriers
- ▶ The most **beneficial actions government agencies could take to increase uptake of buprenorphine** include:
 - ▶ Additional financial assistance to clients to pay for medication
 - ▶ Facilitating access to long-acting buprenorphine
- ▶ Respondents were divided on **criteria for dismissal**
 - ▶ Criteria for dismissal and harm reduction approaches will be explored in qualitative interviews